Janux Therapeutics (JANX) Financials

Janux Therapeutics (NASDAQ: JANX) remains in the classic biotech profile: minimal revenue, persistent operating losses, and a very large cash/investment balance that gives it runway to keep funding research. The latest quarter, Q1 2026, shows the company still burning cash, but it also shows a balance sheet that is substantially stronger than it was a year ago.

• Cash and investments remain very large. Janux ended Q1 2026 with about $956.4 million in cash, cash equivalents, and short-term investments, giving it a strong financial cushion.
• Equity is still high. Total common equity was about $941.5 million at quarter-end, which is a solid base for a development-stage biotech company.
• Balance sheet leverage is low. Total liabilities were only $86.7 million, leaving the company with a relatively clean balance sheet.
• Revenue is starting to appear, but remains small. Q1 2026 revenue was $3.7 million, up from zero in Q2 2025 and in line with the company’s early-stage status.
• Operating cash burn improved year over year. Net cash used in operations was $12.3 million in Q1 2026, better than $17.0 million in Q1 2025 and far better than some earlier quarters.
• R&D spending remains robust. Janux spent $26.8 million on research and development in Q1 2026, showing continued investment in pipeline development.
• Interest and investment income is helping offset losses. The company generated $9.9 million in interest and investment income in Q1 2026, which helped reduce the pre-tax loss.
• Non-cash adjustments continue to support cash flow. The company’s cash flow statement still includes meaningful non-cash items, which is common for biotech but makes earnings less informative than cash and runway.
• The company is still unprofitable. Janux reported a Q1 2026 net loss of $24.4 million, or $(0.39) per share.
• Losses remain persistent across the last several years. Quarterly net losses have generally ranged from roughly $12 million to $34 million, showing no sustained move to profitability yet.

Looking at the trend over the last four years, Janux has moved from a much smaller balance sheet in 2023 to a far stronger cash position today, largely helped by capital raises and investment portfolio growth. In fact, total assets climbed from about $353 million in Q1 2023 to more than $1.0 billion in Q1 2026, while liabilities stayed relatively modest. That is a favorable setup for a clinical-stage biotech because it reduces near-term financing risk.

At the same time, the income statement tells a familiar story: revenue is still tiny relative to spending, and operating expenses continue to outpace any commercial income. Q1 2026 operating expenses of $37.9 million were more than 10 times revenue. That means investors are still betting on pipeline success rather than current earnings power.

Bottom line: Janux Therapeutics looks financially well-capitalized for now, with a strong balance sheet and substantial runway. The main risk is that the company is still far from profitability, so the stock will likely continue to trade on clinical progress and future commercialization potential rather than near-term fundamentals.